| SOPA Images/LightRocket via Getty Images Key Takeaways Amgen is buying Horizon Therapeutics for just over $26 billion, or $116.50 per share. Horizon has two major drugs, Tepezza and Krystexxa, a thy...
| SOPA Images/LightRocket via Getty Images Key Takeaways Amgen is buying Horizon Therapeutics for just over $26 billion, or $116.50 per share. Horizon has two major drugs, Tepezza and Krystexxa, a thy...